Follow The Filings

ELVN Enliven Therapeutics Inc.

Health Care, filed as ENLIVEN THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 2 managers in 2026 Q2

  • 2 Owners
  • Max 4.5%
  • $28M
  • 1 new 1 add

In 2026 Q2 Ron Baron opened a position in Enliven Therapeutics, and David Witzke added.

Who owns this now

Largest portfolio weights among holders, up to 4.5% (David Witzke, Avidity Partners Management). Not free-float ownership.

  1. David Witzke Add 4.5%

Who owns ELVN

Sorted by value, long equity only, as of 2026 Q2.

History
David Witzke, Avidity Partners Management 4.5%, was 3.7% Add +37.5% 550,000 $28M History
Ron Baron, Bamco Inc. (Baron Capital) <0.01% New <0.01% 7,500 $381K History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ELVN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ELVN insider trades
  • None no insider bought on the open market
  • $52.6M sold by 3 insiders outside a trading plan
  • $24.3M sold by 8 insiders under 10b5-1 plans
  1. Benjamin Hohl CFO
    Planned sale
    $232K 6,018 shares at $38.48 14% of stake
    Traded Oct 19 Filed Oct 21
    ↗
  2. Helen Louise Collins Chief Medical Officer
    Planned sale
    $192K 5,000 shares at $38.47 17% of stake
    Traded Oct 19 Filed Oct 21
    ↗
  3. J. Scott Garland Director
    Sale
    $607K 13,000 shares at $46.67 100% of stake
    Traded Oct 1 Filed Oct 5
    ↗
  4. Benjamin Hohl CFO
    Planned sale
    $303K 6,018 shares at $50.35 14% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  5. Helen Louise Collins Chief Medical Officer
    Planned sale
    $252K 5,000 shares at $50.35 17% of stake
    Traded Sep 17 Filed Sep 21
    ↗
  6. Benjamin Hohl CFO
    Planned sale
    $353K 6,018 shares at $58.58 13% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  7. Helen Louise Collins Chief Medical Officer
    Planned sale
    $293K 5,000 shares at $58.59 17% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  8. Mika K Derynck Director
    Planned sale
    $9.6M 158,795 shares at $60.21 100% of stake
    Traded Aug 4 Filed Aug 6
    ↗
  9. Benjamin Hohl CFO
    Planned sale
    $317K 6,018 shares at $52.64 12% of stake
    Traded Jul 17 Filed Jul 21
    ↗
  10. Helen Louise Collins Chief Medical Officer
    Planned sale
    $263K 5,000 shares at $52.67 17% of stake
    Traded Jul 17 Filed Jul 21
    ↗
  11. Lori Anne Kunkel Director
    Planned sale
    $505K 10,000 shares at $50.49 19% of stake
    Traded Jul 6 Filed Jul 8
    ↗
  12. Orbimed Advisors LLC 10% owner, +2 joint filers
    Sale
    $39M 860,123 shares at $45.36 12% of stake
    Traded Jun 22 Filed Jun 24
    ↗
  13. Benjamin Hohl CFO
    Planned sale
    $264K 6,018 shares at $43.80 11% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  14. Helen Louise Collins Chief Medical Officer
    Planned sale
    $219K 5,000 shares at $43.80 17% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  15. Orbimed Advisors LLC 10% owner, +2 joint filers
    Sale
    $12.7M 281,408 shares at $45.02 3.7% of stake
    Traded Jun 15 Filed Jun 17
    ↗

Also filed in the last 12 months, not counted as buying or selling: 23 option exercises and 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 22 shown.

Filed Form Detail Links
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
424B5 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$71.58M -$89.02M -$103.69M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $266.15M $318.13M $474.88M
Total non-current assets * $5.72M $7.63M $1.29M
Total assets $271.87M $325.76M $476.17M
Total current liabilities $25.89M $15.92M $16.57M
Total non-current liabilities * $67,000 $0.00 $0.00
Total equity $245.91M $309.84M $459.6M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$61.27M -$73.19M -$70.3M
Cash from investing -$148.41M -$36M -$173.84M
Cash from financing $234.29M $133.16M $218.87M
Net change in cash * $24.6M $23.98M -$25.28M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.